Peptibase
Metabolic

SLU-PP-332

Also known as: Exercise in a Pill, ERR Agonist SLU-PP-332

Preclinical
Share:

Key Facts: SLU-PP-332

Category
Metabolic
FDA Status
Not FDA Approved
Clinical Status
Preclinical - Animal studies only, no human clinical trials
Administration
Oral (tablets/capsules) most common, subcutaneous injection less common
Typical Dose
250 mcg - 1 mg daily (oral)
Frequency
1-2x daily
Duration
4-8 weeks typical community protocols
Also Known As
Exercise in a Pill, ERR Agonist SLU-PP-332

Mechanism of Action

SLU-PP-332 is a pan-agonist of all three estrogen-related receptor (ERR) isoforms: ERRalpha (EC50 = 98 nM), ERRbeta (230 nM), and ERRgamma (430 nM). It activates an acute aerobic exercise gene program in skeletal muscle, upregulating PGC-1alpha (master regulator of mitochondrial biogenesis), GLUT4 (glucose transporter), and DDIT4 (a key exercise-response protein). This shifts cellular fuel utilization from carbohydrates toward fatty acid oxidation, increases mitochondrial density and function, and promotes conversion of muscle fibers toward oxidative type IIa fibers (endurance fibers). Works through gene transcription, not hormonal feedback loops or nervous system stimulation.

Research Summary

Nine published preclinical studies as of 2026, no human clinical trials. Key findings: Mice ran ~70% longer and ~45% further than controls (ACS Chem Biol, 2023). Diet-induced obese mice lost ~12% body weight in 28 days with 25% increase in fatty acid oxidation and no change in food intake (J Pharmacol Exp Ther, 2024). Improved ejection fraction and survival in heart failure models (Circulation, 2024). Reversed age-related kidney dysfunction and inflammation in old mice (Am J Pathol, 2023). Counteracted muscle atrophy and sarcopenia markers (Frontiers in Physiology, 2025). Mouse dosing: 50 mg/kg IP twice daily.

Trial Progress:Preclinical
Pre
I
II
III
IV
FDA

Dosing Information

Animal Studies·Multiple preclinical studies with strong results, but no human trials

Note: Animal study doses may not translate directly to humans.

Typical Dosingⓘ

Community experience

Common Dose

250 mcg - 1 mg daily (oral)

Range

250 mcg - 1.5 mg per day

Frequency

1-2x daily

Oral is the most common route. Start low at 250 mcg and titrate up. Lower doses (250-500 mcg) typically used for fat loss, higher doses (1-1.5 mg) for performance and lean muscle goals. Some users take it sublingually or via subcutaneous injection for higher bioavailability. Cycling generally not considered necessary due to non-hormonal mechanism, though some protocols suggest 4-8 weeks on with a break.

Research Dosingⓘ

Scientific studies

Community-reported doses. No human clinical data exists.

Duration

4-8 weeks typical community protocols

Administration

Oral (tablets/capsules) most common, subcutaneous injection less common

Timing & Administration

Best Time to Take

Morning, or split morning and afternoon

1-2 times daily, some users split into morning + afternoon doses

Food Recommendation

With or without food

Why This Timing?

Metabolic effects begin within ~2 hours of dosing. Split dosing mimics the twice-daily protocol from mouse studies. Not a stimulant, but morning dosing aligns with natural metabolic rhythms.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Limited safety data (preclinical only)
  • ●Minor cholesterol changes in animal studies
  • ●Minor liver enzyme elevation in animal studies
  • ●Potential cardiac hypertrophy at high doses (ERRs highly expressed in heart)
  • ●Anecdotal: possible lipid changes (decreased HDL, increased LDL)
  • ●Anecdotal: mood changes, irritability (unverified)
  • ●Research chemical quality/contamination risk
  • ●No long-term human safety data
  • ●Not FDA approved for any use

References

Research This Peptide Further

PubMedClinicalTrials.govFDA.gov

Frequently Asked Questions

What does SLU-PP-332 do?

A synthetic small molecule developed at Saint Louis University that activates estrogen-related receptors (ERRs), mimicking the metabolic effects of aerobic exercise. Technically not a peptide but a small organic molecule (MW 290.32), widely discussed in the peptide community as an "exercise mimetic" that boosts fat oxidation, endurance, and mitochondrial function without stimulant effects.

How does SLU-PP-332 work?

SLU-PP-332 is a pan-agonist of all three estrogen-related receptor (ERR) isoforms: ERRalpha (EC50 = 98 nM), ERRbeta (230 nM), and ERRgamma (430 nM). It activates an acute aerobic exercise gene program in skeletal muscle, upregulating PGC-1alpha (master regulator of mitochondrial biogenesis), GLUT4 (glucose transporter), and DDIT4 (a key exercise-response protein). This shifts cellular fuel utilization from carbohydrates toward fatty acid oxidation, increases mitochondrial density and function, and promotes conversion of muscle fibers toward oxidative type IIa fibers (endurance fibers). Works through gene transcription, not hormonal feedback loops or nervous system stimulation.

Is SLU-PP-332 FDA approved?

No, SLU-PP-332 is not currently FDA approved. Current status: Preclinical - Animal studies only, no human clinical trials

What are the side effects of SLU-PP-332?

Reported side effects include: Limited safety data (preclinical only), Minor cholesterol changes in animal studies, Minor liver enzyme elevation in animal studies, Potential cardiac hypertrophy at high doses (ERRs highly expressed in heart), Anecdotal: possible lipid changes (decreased HDL, increased LDL). Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of SLU-PP-332?

Community-reported common dose: 250 mcg - 1 mg daily (oral) (1-2x daily). Range: 250 mcg - 1.5 mg per day. Administration: Oral (tablets/capsules) most common, subcutaneous injection less common. No human clinical trials exist. All dosing is community-reported and experimental. Not FDA approved. Not a peptide. Consult healthcare provider.

Related Peptides

Peptides commonly compared with SLU-PP-332 or used in similar applications.

Pancragen

Clinical Trials

A synthetic tetrapeptide (Lys-Glu-Asp-Trp) bioregulator originally isolated from bovine pancreatic cells. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it directly interacts with DNA to regulate pancreatic gene expression. Studied for age-related metabolic disturbances including type 2 diabetes.

Metabolic

MOTS-c

Preclinical

A mitochondria-derived peptide that regulates metabolic homeostasis. Discovered in 2015, it is being studied for its effects on insulin sensitivity, exercise capacity, and aging.

Hormonal

Crystagen

Preclinical

A tripeptide bioregulator supporting immune system function. Demonstrates age-associated immunoprotective properties in spleen tissue. Part of the Khavinson synthesized peptide series.

Bioregulators

Ventfort

Preclinical

A peptide bioregulator targeting vascular tissue and blood vessels. Derived from blood vessel extracts, it supports healthy vascular function and vessel wall integrity. Part of the Khavinson bioregulator family.

Bioregulators

5-Amino-1MQ

Preclinical

A selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support.

Weight Loss

PNC27

Preclinical

A chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. Selectively kills cancer cells by binding to HDM-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected.

Immune
How to Use SLU-PP-332SLU-PP-332 AlternativesCompare with SimilarBrowse All Peptides

Looking for a trusted vendor?

Pro members get access to verified vendors with quality standards & exclusive discount codes.

View Verified Vendors
PRO

Want updates on SLU-PP-332 research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides